Celltrion has secured approval from South Korea’s Ministry of Food and Drug Safety for a change in the Korean Phase 3 clinical trial plan of CT-P44, its biosimilar candidate to Johnson &amp; Johnson’s multiple myeloma drug Darzalex Faspro

CT-P44 (daratumumab biosimilar) - Celltrion

Sep 7, 2026